Engelsk titel: IL6-174G > C genetic polymorphism influences antidepressant treatment outcome
Läs online
Författare:
Carvalho, Serafim
;
Santos, Marlene
;
Lima, Luís
;
Mota-Pereira, Jorge
;
Pimentel, Paulo
;
Maia, Dulce
;
Correia, Diana
;
Gomes, Sofia
;
Cruz, Agostinho
;
Medeiros, Rui
Språk: Eng
Antal referenser: 23
Dokumenttyp:
Artikel
UI-nummer: 17030076
Sammanfattning
Background: Major depressive disorder is a condition associated with dysregulated cytokine levels; among these, IL6. Furthermore, genetic variations within cytokine genes have been proposed to predict antidepressant treatment outcome.
Objectives: This study aims to evaluate the role of IL6-174G > C and IL6R D358A A > C functional polymorphisms in antidepressant treatment phenotypes, specifically remission, relapse, and treatment resistant depression (TRD).
Methods: The referred polymorphisms were genotyped in 80 MDD patients followed at Hospital Magalhães Lemos, Portugal, within a period of 27 months.
Results: It was found that patients carrying IL6-174 GC genotype present a protection towards the development of TRD (OR = 0.242; 95% CI = 0.068–0.869; p = .038), when compared with GG genotype. Additionally, carriers of IL6-174 CC genotype remit earlier than patients with IL6-174 GG/GC genotypes, with a median time to remission of 6 weeks for CC carriers and 15 weeks for GG or GC carriers (p = .030, Log-rank test). No association was found between IL6R D358A genetic polymorphism and any of the treatment phenotypes evaluated.
Conclusions: The IL6-174G > C polymorphism influences antidepressant treatment outcome in this sub-set of MDD patients, providing a putative mechanistic link for the dysregulated IL-6 levels described in the literature in patients with TRD.